Ken Bartizal insider trades: Trius Therapeutics (TSRX) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Ken reports to the SEC
Open-market buys and sales
5 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jul 1, 2013 | TSRX | ↓ Sell | 2,000 | $8.14 | $16K | Direct | Jul 1, 2013 (0d) |
| Jun 4, 2013 | TSRX | ↓ Sell | 2,000 | $7.90 | $16K | Direct | Jun 4, 2013 (0d) |
| May 24, 2013 | TSRX | ↓ Sell | 12,000 | $7.93 | $95K | Direct | May 28, 2013 (4d) |
| May 14, 2013 | TSRX | ↓ Sell | 12,000 | $7.85 | $94K | Direct | May 16, 2013 (2d) |
| Nov 17, 2011 | TSRX | ↓ Sell | 1,687 | $7.85 | $13K | Direct | Nov 18, 2011 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Ken Bartizal's insider trades
Ken Bartizal is Chief Development Officer at Trius Therapeutics (TSRX). Since Nov 17, 2011, Ken has reported no open-market purchases and 5 sales worth $235K on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (5 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every TSRX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.